Schrodinger
SDGRSchrodinger (SDGR)
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
- 52wk Low
- --
- Float Mkt Cap
- --
- Market Cap
- --
- P/ETTM
- --
- P/EDynamic
- --
- P/EStatic
- --
- EPSTTM
- --
- EPSDynamic
- --
- EPSStatic
- --
- BVPS
- --
- P/B
- --
- Circulating Supply
- --
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- --
- Min lot size
- --
- Currency
- --
Schrodinger Analyst Rating
View moreForecast & Rating
Oct 27, 2026- Strong buy71.43%
- Buy0.00%
- Hold28.57%
- Sell0.00%
- Strong sell0.00%
Daily Events
- Jul, 2
Schrodinger shares surged during regular trading, closing at USD 17.21, up 5.00%, driven by a ~USD 57 million milestone payment following Eli Lilly's ~USD 1.7 billion acquisition of Ajax Therapeutics, a key partner. The stock rallied from a pre-market low of USD 16.30 to a session high of USD 17.21, with a regular-session range of USD 16.69 to USD 17.21. Despite Q1 2026 revenue falling 1.62% YoY to USD 58.59 million and a net loss of USD 60.03 million, the stock has climbed above its 20-day (USD 15.45) and 60-day (USD 13.62) moving averages, remaining 27.54% below its 52-week high of USD 23.75. However, the company remains unprofitable with a negative P/E ratio of 12.43, underscoring its development-stage profile.
